Becton, Dickinson and Company (BDX): Price and Financial Metrics
Becton, Dickinson and Company (BDX)
Today's Latest Price: $221.34 USD
Updated Sep 25 11:54am
Add BDX to WatchlistSign Up
POWR Components:
Trade Grade Buy & Hold Grade Peer Grade Industry Rank
Industry Rank:
Ranked of 138 in Medical - Devices & Equipment
See all "A" rated Strong Buy stocks
BDX Stock Summary
- With a market capitalization of $64,107,328,739, Becton Dickinson & Co has a greater market value than 97.07% of US stocks.
- Becton Dickinson & Co's stock had its IPO on January 1, 1986, making it an older stock than 92.81% of US equities in our set.
- The volatility of Becton Dickinson & Co's share price is greater than that of merely 2.35% US stocks with at least 200 days of trading history.
- Stocks that are quantitatively similar to BDX, based on their financial statements, market capitalization, and price volatility, are BSX, ZTS, SYK, ABB, and SE.
- Visit BDX's SEC page to see the company's official filings. To visit the company's web site, go to www.bd.com.
BDX Stock Price Chart Technical Analysis Charts
BDX Price/Volume Stats
| Current price | $221.34 | 52-week high | $286.72 |
| Prev. close | $221.16 | 52-week low | $197.75 |
| Day low | $219.50 | Volume | 703,257 |
| Day high | $222.55 | Avg. volume | 1,992,432 |
| 50-day MA | $252.47 | Dividend yield | 1.43% |
| 200-day MA | $252.31 | Market Cap | 64.16B |
Becton, Dickinson and Company (BDX) Company Bio
Becton, Dickinson and Company provides solutions which are focused on improving medication management and patient safety, supporting infection prevention practices, equipping surgical and interventional procedures, improving drug delivery, aiding anesthesiology and respiratory care, advancing cellular research and applications, enhancing the diagnosis of infectious diseases and cancers, and supporting the management of diabetes. The company was founded in 1897 and is based in Franklin Lakes, New Jersey.
BDX Price Forecast Based on DCF Valuation
| Current Price | DCF Fair Value Target: | Forecasted Gain: |
| $221.34 | $160.68 | -27% |
The table below illustrates the output of a discounted cash flow forecast using a variety of scenarios for Becton Dickinson & Co. To summarize, we found that Becton Dickinson & Co ranked in the 36th percentile in terms of potential gain offered. Our DCF analysis suggests the stock is overvalued by about 27%. The most interesting components of our discounted cash flow analysis for Becton Dickinson & Co ended up being:
- The company has produced more trailing twelve month cash flow than 87.45% of its sector Healthcare.
- Becton Dickinson & Co's weighted average cost of capital (WACC) is 8%; for context, that number is higher than only 22.45% of tickers in our DCF set.
- Becton Dickinson & Co's effective tax rate, as measured by taxes paid relative to net income, is at 0 -- greater than only 0% of US stocks with positive free cash flow.
| Terminal Growth Rate in Free Cash Flow | Return Relative to Current Share Price |
| 0% | -29% |
| 1% | -28% |
| 2% | -27% |
| 3% | -27% |
| 4% | -26% |
| 5% | -25% |
For other companies in the Healthcare that have a similar discounted cashflow valuation profile (and ensuing price forecasts) as BDX, try IQV, ITGR, EDAP, CRL, and NVS.
Loading social stream, please wait...